益气养心定志方治疗慢性阻塞性肺疾病患者焦虑状态临床研究  

Clinical Study on Yiqi Yangxin Dingzhi Prescription for Anxiety State of Patients with Chronic Obstructive Pulmonary Disease

作　　者：吴蔚[1] 王彬[1] 刘惠梅 杨国华[1] 高峰[1] WU Wei;WANG Bin;LIU Hui-mei;YANG Guo-hua;GAO Feng(Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China)

机构地区：[1]中国中医科学院望京医院,北京100102

出　　处：《中国中医药信息杂志》2018年第7期25-29,共5页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：北京市中医药科技项目(JJ2014-67)

摘　　要：目的观察益气养心定志方对慢性阻塞性肺疾病(COPD)患者焦虑状态的影响。方法采用区组随机、平行对照、单盲法将80例患者分为观察组和对照组各40例。2组均予COPD稳定期维持治疗,在此基础上,观察组予益气养心定志方颗粒,对照组予中药模拟颗粒,每日1剂,每日2次冲服。连续治疗2周。观察2组治疗前后中医症状评分、慢性阻塞性肺疾病评估测试(CAT)评分、汉密顿焦虑量表(HAMA)评分,并监测安全性指标。结果与本组治疗前比较,2组治疗后中医症状评分、CAT评分、HAMA评分明显降低(P<0.05);治疗后观察组和对照组中医症状总分改善程度[(5.04±1.90)分vs(2.27±1.83)分]、CAT评分改善程度[(4.51±1.36)分vs(1.81±1.47)分]及HAMA总分改善程度[(5.32±2.78)分vs(2.76±1.19)分]比较,观察组优于对照组,差异有统计学意义(P<0.05)。2组均未发生明显不良事件。结论益气养心定志方可有效缓解稳定期COPD患者的焦虑状态,改善其生活质量,安全性良好。Objective To observe the effects of Yiqi Yangxin Dingzhi Prescription on anxiety state of patients with chronic obstructive pulmonary disease（COPD）. Methods Randomized, parallel controled, single-blind research plan was used. Totally 80 patients with COPD were randomly divided into observation group and control group, with 40 cases in each group. Both groups received COPD stable maintenance treatment. On this basis, observation group was given Yiqi Yangxin Dingzhi Granules, while control group was given TCM simulator, one dosage per day, twice a day. The treatment lasted for two weeks both groups. TCM symptom scores, COPD assessment test（CAT） scores, and Hamilton Anxiety Scale（HAMA） scores before and after treatment in the two groups were observed. The safety indexes were monitored. Results Compared with before treatment, the TCM symptom scores, CAT scores, and HAMA scores of the two groups after treatment were significantly lower（P0.05）. After treatment, the improvement degree of the TCM symptom total scores [（5.04±1.90） vs（2.27±1.83）, the improvement degree of the CAT total score [（4.51±1.36） vs（1.81±1.47）], and the improvement degree of the HAMA total score [（5.32±2.78） vs（2.76±1.19）] in the observation group were better than the control group, with statistical significance（P0.05）. No significant adverse events occurred in both groups. Conclusion Yiqi Yangxin Dingzhi Prescription can effectively improve the clinical symptoms of the patients with COPD and the life quality of the patients, and it has high safety.

关 键 词：慢性阻塞性肺疾病 焦虑状态 益气养心定志方 

分 类 号：R259.63[医药卫生—中西医结合]